VYNE Therapeutics Files 8-K
Ticker: VYNE · Form: 8-K · Filed: Dec 23, 2024 · CIK: 1566044
| Field | Detail |
|---|---|
| Company | Vyne Therapeutics Inc. (VYNE) |
| Form Type | 8-K |
| Filed Date | Dec 23, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-filing, financials
TL;DR
VYNE Therapeutics filed an 8-K on 12/23/24 for routine updates.
AI Summary
VYNE Therapeutics Inc. filed an 8-K on December 23, 2024, reporting other events and financial statements. The company, formerly known as Menlo Therapeutics Inc. and Tigercat Pharma, Inc., is incorporated in Delaware and headquartered in Bridgewater, NJ.
Why It Matters
This filing indicates routine corporate reporting, providing updates on events and financial statements for VYNE Therapeutics Inc.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting events and financial statements, not indicating any immediate material changes or risks.
Key Players & Entities
- VYNE Therapeutics Inc. (company) — Registrant
- Menlo Therapeutics Inc. (company) — Former company name
- Tigercat Pharma, Inc. (company) — Former company name
- December 23, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Bridgewater, New Jersey (location) — Principal business address
FAQ
What is the primary purpose of this 8-K filing for VYNE Therapeutics Inc.?
The filing is a Current Report on Form 8-K, reporting 'Other Events' and 'Financial Statements and Exhibits' as of December 23, 2024.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on December 23, 2024.
What were VYNE Therapeutics Inc.'s former company names?
VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc. (name change effective 20180201) and also previously as Menlo Therapeutics, Inc. (name change effective 20170728) and Tigercat Pharma, Inc. (name change effective 20130104).
In which state is VYNE Therapeutics Inc. incorporated?
VYNE Therapeutics Inc. is incorporated in Delaware.
What is the principal business address of VYNE Therapeutics Inc.?
The principal business address is 685 Route 202/206 N., Suite 301, Bridgewater, New Jersey 08807.
Filing Stats: 472 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-12-23 07:42:43
Key Financial Figures
- $0.0001 — e on which registered Common Stock, $0.0001 par value VYNE The Nasdaq Stock Mar
Filing Documents
- tm2431817d1_8k.htm (8-K) — 26KB
- tm2431817d1_ex99-1.htm (EX-99.1) — 22KB
- tm2431817d1_ex99-2.htm (EX-99.2) — 27KB
- tm2431817d1_ex99-1img001.jpg (GRAPHIC) — 7KB
- tm2431817d1_ex99-2img001.jpg (GRAPHIC) — 162KB
- tm2431817d1_ex99-2img002.jpg (GRAPHIC) — 293KB
- tm2431817d1_ex99-2img003.jpg (GRAPHIC) — 138KB
- tm2431817d1_ex99-2img004.jpg (GRAPHIC) — 181KB
- tm2431817d1_ex99-2img005.jpg (GRAPHIC) — 177KB
- tm2431817d1_ex99-2img006.jpg (GRAPHIC) — 154KB
- tm2431817d1_ex99-2img007.jpg (GRAPHIC) — 485KB
- tm2431817d1_ex99-2img008.jpg (GRAPHIC) — 385KB
- tm2431817d1_ex99-2img009.jpg (GRAPHIC) — 46KB
- tm2431817d1_ex99-2img010.jpg (GRAPHIC) — 133KB
- tm2431817d1_ex99-2img011.jpg (GRAPHIC) — 151KB
- tm2431817d1_ex99-2img012.jpg (GRAPHIC) — 169KB
- tm2431817d1_ex99-2img013.jpg (GRAPHIC) — 160KB
- tm2431817d1_ex99-2img014.jpg (GRAPHIC) — 149KB
- tm2431817d1_ex99-2img015.jpg (GRAPHIC) — 143KB
- tm2431817d1_ex99-2img016.jpg (GRAPHIC) — 149KB
- tm2431817d1_ex99-2img017.jpg (GRAPHIC) — 221KB
- 0001104659-24-131064.txt ( ) — 4811KB
- vyne-20241223.xsd (EX-101.SCH) — 3KB
- vyne-20241223_lab.xml (EX-101.LAB) — 33KB
- vyne-20241223_pre.xml (EX-101.PRE) — 22KB
- tm2431817d1_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On December 23, 2024, VYNE Therapeutics Inc. (the " Company ") issued a press release entitled "VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor." In addition, on December 23, 2024, the Company posted a presentation that includes data from its Phase 1a trial of VYN202 on its website. A copy of the Company's press release and presentation are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated by reference herein.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits The following exhibits are being filed herewith. Exhibit No. Description 99.1 Press Release, dated December 23, 2024. 99.2 Presentation, dated December 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VYNE THERAPEUTICS INC . Date: December 23, 2024 By: /s/ Mutya Harsch Mutya Harsch Chief Legal Officer and General Counsel 2